Drug-Induced QT Prolongation

The medications you prescribe or administer can save a life—or inadvertently trigger a fatal arrhythmia. Drug-induced QT interval prolongation is a critical pharmacovigilance concern because it creates an electrical vulnerability in the heart that can degenerate into torsades de pointes (TdP), a polymorphic ventricular tachycardia, and sudden cardiac death. Understanding this risk is non-negotiable for safe clinical practice, as it involves common drugs across many specialties, from antibiotics and antipsychotics to antiemetics and antiarrhythmics.

The Electrophysiological Basis: Delaying Ventricular Repolarization

At its core, the QT interval on an electrocardiogram (ECG) represents the total time for ventricular depolarization and repolarization. Drug-induced prolongation specifically targets the repolarization phase. The crucial player is the delayed rectifier potassium current ($I_{Kr}$), which is primarily carried by channels encoded by the hERG gene. This current is essential for terminating the cardiac action potential and returning the myocardium to its resting state.

Many drugs, or their metabolites, directly block the $I_{Kr}$ channel. This blockade slows the efflux of potassium ions from the cardiac myocyte, prolonging the action potential duration and, consequently, the QT interval on the surface ECG. Think of repolarization as a coordinated exit ramp for electrical activity; when this exit is blocked, the electrical activity lingers dangerously. This prolonged state increases the likelihood of abnormal electrical triggers called early afterdepolarizations (EADs), which are the initiating beats for torsades de pointes. The corrected QT interval (QTc), adjusted for heart rate, is the key clinical metric, with values >500 ms or an increase >60 ms from baseline signifying high risk.

Common Offenders: High-Risk Drug Classes

While hundreds of drugs carry warnings, certain classes are notorious for their QT-prolonging potential. Awareness of these is the first step in risk mitigation.

• Class III Antiarrhythmics: Ironically, drugs like amiodarone, dofetilide, and sotalol are prescribed for arrhythmias but work by prolonging the action potential. They carry a significant, dose-dependent risk for TdP, mandating initiation in a monitored setting.
• Antimicrobials:
• Fluoroquinolones (e.g., levofloxacin, moxifloxacin) vary in risk, with moxifloxacin posing a greater threat.
• Macrolides (e.g., erythromycin, clarithromycin) inhibit the $I_{Kr}$ channel and can also inhibit the metabolism of other QT-prolonging drugs, creating a dangerous synergistic effect. Azithromycin is generally considered lower risk.
• Antipsychotics: Both typical (e.g., haloperidol) and atypical (e.g., ziprasidone, quetiapine) agents can prolong the QTc. The risk is heightened with IV administration, high doses, or rapid titration.
• Methadone: This opioid maintenance therapy is a potent $I_{Kr}$ blocker. Its long half-life means the risk is sustained, requiring baseline and periodic ECG monitoring, especially during dose escalation.
• Others: Numerous other agents, including certain antiemetics (ondansetron, droperidol), antidepressants, and antifungal agents, contribute to a long list that clinicians must regularly consult.

Compounding Risk: Patient-Specific Factors

Drug exposure alone is often insufficient to cause TdP; it typically requires a "perfect storm" of patient-specific risk factors that further impair repolarization reserve.

• Electrolyte Disturbances: Hypokalemia and hypomagnesemia are major amplifiers of risk. Low extracellular potassium paradoxically enhances drug binding to and blockade of the $I_{Kr}$ channel. Magnesium is a natural calcium channel blocker that stabilizes the myocardium and suppresses EADs.
• Underlying Cardiac Disease: Heart failure, bradycardia, and left ventricular hypertrophy create a substrate more susceptible to arrhythmogenesis.
• Inherent Vulnerability: Female sex (due to hormonal influences on cardiac currents), congenital long QT syndrome, and advanced age are significant non-modifiable risk factors.
• Polypharmacy: The concurrent use of multiple QT-prolonging drugs has an additive, and sometimes synergistic, effect. Furthermore, pharmacokinetic interactions—where one drug inhibits the metabolism of another, raising its serum concentration—are a common trigger. CYP3A4 and CYP2D6 inhibitors are frequent culprits in these dangerous interactions.

From Prolongation to Crisis: Torsades de Pointes Pathophysiology

When a prolonged QT interval (a vulnerable substrate) is punctuated by an early afterdepolarization (a trigger), the result can be torsades de pointes. This distinctive arrhythmia is characterized by a twisting of the QRS axis around the isoelectric line on the ECG. It often presents with sudden syncope, palpitations, or dizziness. While TdP can be self-terminating, it can also degenerate into ventricular fibrillation, leading to cardiac arrest.

The mechanism is rooted in transmural dispersion of repolarization (TDR). Drug blockade of $I_{Kr}$ is not uniform across the ventricular wall; it disproportionately affects certain cell layers (like M cells), creating electrical heterogeneity. This dispersion sets the stage for a re-entrant circuit, which manifests as the spiraling pattern of TdP.

Acute Management and Long-Term Prevention

Acute Management of Torsades de Pointes

The immediate treatment is protocol-driven:

1. Discontinue the Offending Agent: This is the absolute first step.
2. IV Magnesium Sulfate: This is the first-line pharmacologic therapy, even if serum magnesium levels are normal. A typical load is 1-2 grams IV over 5-15 minutes. Magnesium does not shorten the QTc but suppresses EADs by blocking calcium influx.
3. Correct Electrolytes: Aggressively replete potassium to high-normal levels (≥4.5 mEq/L).
4. Increase Heart Rate: Temporarily increasing the ventricular rate shortens the QT interval. This can be achieved with transcutaneous pacing or an isoproterenol infusion (if the patient is not ischemic).
5. Defibrillation: If TdP degenerates into ventricular fibrillation, immediate defibrillation is required.

Clinical Strategies for Minimizing Risk

Prevention is paramount, especially in polypharmacy settings:

• Risk Assessment: Prior to prescribing a known QT-prolonging drug, perform a baseline risk assessment. This includes a review of concomitant medications, checking electrolytes, and obtaining a baseline ECG for high-risk patients or drugs.
• ECG Monitoring Protocol: Know when to monitor. For high-risk drugs like dofetilide or methadone initiation, protocolized ECG monitoring is mandatory. For others, a prudent approach is to check a QTc at baseline, after dose escalation, and with any change in interacting medications.
• The Principle of Substitution: Where clinically equivalent alternatives exist, choose the agent with lower QT-prolonging potential (e.g., choosing azithromycin over clarithromycin when appropriate).
• Manage Modifiable Risks: Vigilantly maintain normokalemia and normomagnesemia in hospitalized patients on multiple drugs.
• Leverage Clinical Decision Support: Utilize pharmacy alerts and updated resources like the CredibleMeds.org database to screen for drug-drug interactions and high-risk combinations.

Common Pitfalls

• Ignoring Drug-Drug Interactions: Prescribing a macrolide antibiotic to a patient already on a stable dose of a typical antipsychotic can precipitously increase the antipsychotic level and QTc. Always screen for metabolic interactions.
• Overlooking "Non-Cardiac" Drugs: Assuming only antiarrhythmics are dangerous. Fatal TdP has been precipitated by common antibiotics, antiemetics, and antidepressants.
• Incorrect QTc Calculation: Failing to use a consistent formula (Bazett's is most common but over-corrects at high heart rates; Fridericia's may be better) or mis-measuring the QT interval can lead to false reassurance. Use ECG machine calculations with verification.
• Delaying Magnesium Administration: Waiting for a serum magnesium result before treating an acute episode of TdP is incorrect. IV magnesium is a stabilizing treatment based on the clinical scenario, not the lab value.

Summary

• Drug-induced QT prolongation occurs primarily through blockade of the $I_{Kr}$ potassium channel, delaying ventricular repolarization and creating a substrate for torsades de pointes (TdP).
• High-risk drug classes include class III antiarrhythmics, fluoroquinolones, macrolides, antipsychotics, and methadone, among many others.
• Patient risk is magnified by hypokalemia, hypomagnesemia, female sex, bradycardia, and the concurrent use of multiple QT-prolonging drugs (polypharmacy).
• The acute management of TdP centers on immediate discontinuation of the culprit drug, IV magnesium sulfate, electrolyte repletion, and measures to increase heart rate.
• Prevention requires proactive risk assessment, strategic ECG monitoring, careful drug selection, and diligent management of modifiable risk factors like electrolyte imbalances.